190 related articles for article (PubMed ID: 1184969)
21. Heterologous antiserum to a subpopulation of thymocytes and lymphomas in rats.
Moriuchi T; Kasai M; Kobayashi H
Gan; 1979 Dec; 70(6):825-8. PubMed ID: 317055
[TBL] [Abstract][Full Text] [Related]
22. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
23. Effect of splenectomy on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).
Havas HF; Berney S; Goodis A; Schiffman G
Cancer Res; 1979 Sep; 39(9):3783-7. PubMed ID: 476702
[TBL] [Abstract][Full Text] [Related]
24. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
Takesue BY; Pyle JM; Mokyr MB
Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
[TBL] [Abstract][Full Text] [Related]
25. Proportional absorption. A method for determination of the relative specificity of antisera prepared against cells.
Reif AE; Robinson CM
Immunology; 1975 Jan; 28(1):199-205. PubMed ID: 1090519
[TBL] [Abstract][Full Text] [Related]
26. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
27. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
Wang KC; Berczi I; Sehon AH
Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
[TBL] [Abstract][Full Text] [Related]
28. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
29. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
30. Murine plasma cells secreting more than one class of immunoglobulin heavy chain. II. SAMM 368--a plasmacytoma secreting IgG2b-kappa and IgA-kappa immunoglobulins which do not share idiotypic determinants.
Morse HC; Neiders ME; Lieberman R; Lawton AR; Asofsky R
J Immunol; 1977 May; 118(5):1682-9. PubMed ID: 67144
[TBL] [Abstract][Full Text] [Related]
31. The requirement of Ia-positive accessory cells for the induction of hapten-reactive cytotoxic T lymphocytes in vitro.
Yamashita U; Hamaoka T
J Immunol; 1979 Dec; 123(6):2637-43. PubMed ID: 315427
[No Abstract] [Full Text] [Related]
32. The relationship between secreted and cell surface antigen-binding molecules synthesized by T cells. I. Function-related isotypic determinants on T cells defined by antisera to antigen-specific helper and suppressor factors.
Culbert EJ; Kontiainen S; Feldmann M
Immunology; 1984 Nov; 53(3):481-90. PubMed ID: 6208146
[TBL] [Abstract][Full Text] [Related]
33. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
34. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
[TBL] [Abstract][Full Text] [Related]
35. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
37. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations.
Ono S; Natsu-ume S; Migita S
J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090
[TBL] [Abstract][Full Text] [Related]
38. Isolation of a specific plasmacytoma tumor antigen, reactive both in humoral and cell mediated immunity.
Kolb JP; Lespinats G; Poupon MF
Ann Immunol (Paris); 1974; 125 C(5):835-45. PubMed ID: 4142374
[No Abstract] [Full Text] [Related]
39. The mode of action of splenic suppressor cells in murine plasmacytoma.
Chen Y; Heller P
Clin Exp Immunol; 1981 Sep; 45(3):514-22. PubMed ID: 6461449
[TBL] [Abstract][Full Text] [Related]
40. Tumor immunity to murine plasma cell tumors. V. Genetic control of the in vitro cytotoxic T-cell response to plasma cell tumor-associated antigens of NZB mice.
Burton RC; Warner NL
J Natl Cancer Inst; 1980 Aug; 65(2):431-40. PubMed ID: 6967529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
